Phase II Study of Paclitaxel and Cisplatin as Second-line Chemotherapy in Advanced Non-small Cell Lung Cancer

진행성 비소세포폐암에 대한 2차 화학요법으로 paclitaxel과 cisplatin의 제 2상 임상연구

Background: To evaluate the efficacy and safety of paclitaxel and cisplatin against advanced non-small cell lung cancer (NSCLC) as a second-line chemotherapy. Subjects and Methods: Twenty-five patients were enrolled. The patients received 200 $mg/m^2$ paclitaxel as a 3-hour intravenous infusion and 60 $mg/m^2$ cisplatin as 2D-minute intravenous infusion with vigorous hydration on day 1 every 28 days. The response was assessed every 2 cycles. Results: All 25 patients were assessed for their response and toxicity. Partial responses were observed in 5 patients. The overall response rate was 20%(95% confidence interval, 4%-36%) and the median response duration was 4.5(range, 2-11) months. The median time to progression was 3.3(range, 0-14) months. The median overall survival of all patients was 7.4(range, 1.3-39) months. The hematologic toxicities were minor and easily controlled. Conclusion: The combination chemotherapy of paclitaxel and cisplatin as a second-line treatment has a moderate efficacy with an acceptable toxicity in patients with advanced NSCLC.

gemcitabine과 carboplatin으로 치료받은 경력이 있는 진행성 비소세포폐암 환자 25명을 대상으로 2차 화학요법으로 paclitaxel과 cisplatin을 사용하여 다음과 같은 결과를 확인하였다. 전체 25명 중 5명에서 부분반응이 관찰되었으며, 반응군의 반응지속기간은 2~11개월로 중앙값 4.3개월이었다. 전체 환자의 무진행생존 기간은 0~11개월로 중앙값 3.3개월이었으며, 생존기간은 1.3~39개월로 중앙값 7.4개월이었다. 전체 83회의 화학요법 중 WHO 3도의 혈소판감소증이 1회에서만 관찰되었으며, 비혈액학적 부작용도 감내할만 하였다. 이상의 결과 paclitaxel과 cisplatin 복합화학 요법은 진행서 비소세포폐암 환자에서 2차 요법으로 사용하였을 때 부작용이 적으며 효과적인 치료법의 하나로 판단된다.